Unicharm Corporation (UNICY) Fair Value & Analysis
Consumer Defensive · US · Market cap $9.6B
Analysis
Unicharm Corporation (UNICY) currently trades at $2.79, while our model-based Fair Value estimate is $3.12 — implying the stock looks roughly 11.8% undervalued today. We read business quality at 83/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Unicharm Corporation engages in the manufacturing and sale of pet care and related products in Japan and internationally. The company operates through Personal Care, Pet Care, and Others segments. It offers wellness care, feminine care, baby and child care products, as well as food-packaging materials, etc. The company also provides napkin-type incontinence pads, pants-type diapers, tape-type diapers, pants-type specialized urine pads, and tape-type specialized urine pads under the Lifree brand name; specialized liners for incontinence care under the Charm Nap brand name; fabric and facial masks under the Chorittai and Chokaiteki Mask brand name; Home care products under Wave brand; and kitchen paper towel under the Cook Up brand name. In addition, it offers pet food under the Pet Dog Genki, Pet Cat Genki, Grand Deli, Best Balance, Silver Spoon, Silver Plate, AllWell, and Physicalife brand names, as well as excrement cleanup sheets, disposable diapers, apparel-like absorption wear f…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.